Akari Therapeutics, Plc announced on June 18, 2025, that the Intellectual Property India (IPI) issued Patent No. 562,919, titled “Thailanstatin Analogs.” This patent covers claims for the company’s potent immuno-oncology PH1 payload, proprietary non-cleavable and cleavable linkers, and ADC technology.
The PH1 payload is a spliceosome inhibitor designed to disrupt RNA splicing within cancer cells, leading to cell death and activation of the immune system. This mechanism differentiates it from current ADC payloads that use tubulin inhibitors or DNA damaging agents.
This issued India patent is a divisional patent of the company’s R&D toxin portfolio on PH1 and builds on previously issued patents in the US, China, and Israel. The patent strengthens Akari's global intellectual property estate and provides protection for its CMC manufacturing activities for the PH1 payload and related analogs.
Abizer Gaslightwala, President and CEO of Akari, stated that bolstering the intellectual property portfolio in India is significant due to the rapidly growing incidence rate of cancer cases in the country, projected to increase to 2.08 million by 2040.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.